MK684a-010KEYVIBE
01 May 2023
Trial Summary
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.
Acronym:
MK684a-010KEYVIBE
ACTRN/NCT /ethics:
NCT05665595
Scientific title:
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
Sponsor / Cooperative group:
Merck Sharp & Dohme LLC
Trial & Patient Characteristics
| Cancer Type | Melanoma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 12 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2023-01-19 |
| Anticipated End Date | 2031-03-31 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| Anne.Milton@sa.gv.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Michael Brown |
| Recruitment Status | Recruiting |